Avid Bioservices Inc (CDMO)

[biopharm]

Peregrine Pharmaceuticals : KOL Hakan Mellstedt

Ok.... digging deeper, we have Advisor: Dr. Mahmoud Jeddi-Tehrani, tied directly into Peregrine KOL Hakan Mellstedt:
If you look at the publications... Hakan Mellstedt is all over the place with Dr Mahmoud Jeddi-Tehrani, and Dr. Jeddi-Tehrani has roots back in Karolinska, home of Hakan Mellstedt

.... just a little clip from one of the many chain of posts re: Hakan Mellstedt and to continue on and see how he is playing into this Peregrine puzzle and how it will unfold. First to show the top co-authors again of Hakan M:

---------------------------

Hakan Mellstedt:

Top Co-authors View all

Jan-Erik Frodin (58)
Karolinska Institutet

Peter Ragnhammar (41)
Karolinska Institutet

Mahmood Jeddi-Tehrani (36)
Avicenna Research Institute

Giuseppe Masucci (34)
Karolinska Institutet

Eva Kimby (32)
Karolinska University Hospital

http://www.researchgate.net/profile/Hakan_Mellstedt

-----------------------------------------------

Now one of the last posts spoke of possibly "Mahmood Jeddi-Tehrani" is one of the reasons why Peregrine has the sudden rise of followers from the Middle East regions, because Dr. Jeddi-Tehrani is based in Iran.

For now though... lets look at Peter Ragnhammar and he happens to be on a very recent publication with Peregrine KOL Hakan Mellstedt and its all based around ones immune system and well, we are entering the immunotherapy age of medicine so I think its relevant and since Hakan was brought on board with Peregrine and Bavituximab is a PS Targeting agent which reduces MDSC's and provides that optimal boost to ones immune system, maybe connect the dots are in order:

---------------------------------------------

Induction of Anti-Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (Escherichia coli-Derived) Antibodies and Clinical Effects in Nonimmunocompromised Patients

Authors: Peter Ragnhammar, Heinz-Jurgen Friesen, Jan-Erik Frodin, Ann-Kari Lefvert, Moustapha Hassan, Anders Osterborg, and HAkan Mellstedt

The pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), induction of anti-GM-CSF antibodies, and clinical effects related to the induction of the antibodies were analyzed in patients with metastatic colorectal carcinoma (CRC) who were not on chemotherapy.
..
..
pg 7 of 11 -- See Table 4.. breaks down MDSC's (white blood cells)
.

pg 8 of 11 ** ...The results are in agreement with the notion that GM-CSF mainly affects maturatiodproliferation of hematopoetic cells of the myeloid and monocytic lineages. An alternative explanation to the lower leucocyte counts at subsequent cycles may be a decreased capacity of bone marrow to be stimulated by GM-CSF. Moreover, at cycle IV, systemic side effects of GM-CSF (myalgia, fever, rash/pruritus, conjunctivitis, headache, and nausea) were markedly reduced as compared with the previous cycles, which may be related to the induction of anti-GM-CSF antibodies.

http://www.bloodjournal.org/content/bloodjournal/84/12/4078.full.pdf?sso-checked=true

-----------------------------------------------

For those that have not been following WBC = white blood cells vs MDSC's vs cancer..etc, I'll post the link below just to refresh those memories:

For years, researchers have known that a diverse group of white blood cells called myeloid-derived suppressor cells (MDSC) are more abundant in cancer patients than in healthy individuals.
..
..
"We have identified the monocytic cells as the important cell to target, not only in cancer but possibly for treatment of autoimmune disorders like rheumatoid arthritis or inflammatory bowel diseases where dampening the immune response could provide relief," said corresponding author Peter Murray, Ph.D., a member of the St. Jude departments of Infectious Diseases and Immunology. "We also identified growth factors and other molecules essential to the survival and function of these monocytic cells. Targeting these molecules could lead to more precise approaches for controlling the immune response at the tumor site.

"This study marks a significant step in efforts to understand, develop and optimize immunotherapies for treatment of cancer," he said.

http://www.stjude.org/murray-t-cell

-----------------------------------------------

I thought I remember seeing that St. Jude article most recently... posted about it 12/20 and this is what happens when juggling puzzle pieces from every corner of the earth, even Australia... where Dr. Murray is from! and yes, the same Australia where Peregrine decided they needed a 50k Ball Room and a boat load said it was a waste of money. We shall see about that : )

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109246804&txt2find=murray|st|jude